Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation

2016-05-23 12:28:10 | BioPortfolio


To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or Epstein Barr virus (EBV) or fungi including Aspergillus and Candida species for the treatment of viral infection following allogeneic blood or marrow stem cell or solid organ transplantation.


The study will analyse the safety and biological efficacy of administering the investigational products (most closely HLA-matched third party donor-derived T cells stimulated with viral or fungal antigen expressing DC), for the treatment of viral reactivation and/or infection or fungal infection following allogeneic blood or marrow or solid organ transplantation. The cells will be given therapeutically after transplantation in patients with active viral reactivation or proven/probably fungal infection despite standard therapy.

Our AIMS are to study the safety of third party donor-derived CTL infusions, their effect on treatment of viral reactivation as well as their effect on reconstitution of virus- and fungus-specific immunity, viral and fungal infection and reactivation rates after transplantation, viral load, and use of antiviral and antifungal pharmacotherapy.

We will evaluate the safety of infusions with respect to the development of adverse events within the first 12 months post-CTL infusion and the dynamics of cell persistence by T-cell chimerism analysis.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


CMV Infection


Virus specific CTLs


Westmead Hospital
New South Wales




University of Sydney

Results (where available)

View Results


Published on BioPortfolio: 2016-05-23T12:28:10-0400

Clinical Trials [1372 Associated Clinical Trials listed on BioPortfolio]

Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation

Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) result in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients in China. Antiviral drugs are us...

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolesce...

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

Patients who may have been infected with EBV (Epstein-Barr Virus) before or after the time of their transplant have a higher risk of developing Lymphoproliferative Disease (LPD) or may alr...

BK Specific Cytotoxic T Lymphocytes (CTL) Lines for Stem Cell Transplant (SCT) Recipients

The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) to patients who have had a stem cell transplant can help to control BK viral infection. Resea...

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory ...

PubMed Articles [14695 Associated PubMed Articles listed on BioPortfolio]

In vitro inhibition of HIV-1 replication in autologous CD4(+) T cells indicates viral containment by multifactorial mechanisms.

HIV-1-specific cytotoxic T lymphocytes (CTLs) and neutralizing antibodies (NAbs) are present during chronic infection, but the relative contributions of these effector mechanisms to viral containment ...

Diagnosis of Zika virus infection on a nanotechnology platform.

We developed a multiplexed assay on a plasmonic-gold platform for measuring IgG and IgA antibodies and IgG avidity against both Zika virus (ZIKV) and dengue virus (DENV) infections. In contrast to IgM...

Control of HIV-1 by an HLA-B*52:01-C*12:02 protective haplotype.

HLA-B*52:01-C*12:02, which is found in approximately 20 % of all Japanese, is well known to be associated with ulcerative colitis and Takayasu arteritis. This haplotype is also known to be a protectiv...

Tobacco mosaic virus infection disproportionately impacts phloem associated translatomes in Arabidopsis thaliana and Nicotiana benthamiana.

In this study we use vascular specific promoters and a translating ribosome affinity purification strategy to identify phloem associated translatome responses to infection by tobacco mosaic virus (TMV...

The role of oxidative stress in influenza virus infection.

Virus-induced oxidative stress plays an important role in the regulation of the host immune system. In this review, we provide backgrounds of the pathogenic mechanism of oxidative stress induced by in...

Medical and Biotech [MESH] Definitions

A phenomenon in which infection by a first virus results in resistance of cells or tissues to infection by a second, unrelated virus.

A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, however, may be associated with other neurological and autoimmune complications (e.g., GUILLAIN-BARRE SYNDROME; and MICROCEPHALY).

A species of POLYOMAVIRUS, originally isolated from the brain of a patient with progressive multifocal leukoencephalopathy. The patient's initials J.C. gave the virus its name. Infection is not accompanied by any apparent illness but serious demyelinating disease can appear later, probably following reactivation of latent virus.

An RNA virus infection of rhesus, vervet, and squirrel monkeys transmissible to man.

An infection at a specific location that may spread to another region of the body.

More From BioPortfolio on "Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation"

Quick Search

Searches Linking to this Trial